title: Efficacy of ivermectin and albendazole alone and in combination for treatment of soil-transmitted helminths in pregnancy and adverse events: a randomized open label controlled intervention trial in Masindi district, western Uganda.
abstract: A randomized open-label trial, including 834 pregnant women, examined efficacy and recorded adverse events of ivermectin (ivc) and albendazole (alb) alone and combined (comb) on soil-transmitted helminth infections (STHs) in the second trimester of pregnancy. One abortion occurred in the alb group and 10 stillbirths (1, 5, 3, and 1) in the ivc, alb, comb, and the reference group (ref) with no STHs, respectively. Two babies were born with congenital abnormalities (1 [ivc] and 1 [ref]). The prevalence of anemia at first antenatal care (ANC) visit was 20.6% (23.7% [ivc], 21.1% [alb], 22.2% [comb], and 16.1% [ref]). Anemia was reduced to 8.5% at 36 weeks of gestation with 10.9% (ivc), 11.5% (alb), 7.7% (comb), and 6.9% (ref). Hookworm cure rates were 29.4% (ivc), 95.5% (alb), and 92.6% (comb). No severe adverse events were reported by the women after the administration of ivc, alb, or comb during the second trimester of pregnancy, but long-term pharmacovigillance is needed to assess safety of ivc, alb, or comb in pregnancy.
authors.affiliation: Vector Control Division, Ministry of Health, Kampala, Uganda. notf@vcdmoh.go.ug
authors.forename: Richard
authors.initials: R
authors.lastname: Ndyomugyenyi
authors.forename: Narcis
authors.initials: N
authors.lastname: Kabatereine
authors.forename: Annette
authors.initials: A
authors.lastname: Olsen
authors.forename: Pascal
authors.initials: P
authors.lastname: Magnussen
mesh_terms: D000022:Abortion, Spontaneous; D015766:Albendazole / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use*; D000977:Antiparasitic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D001724:Birth Weight; D000013:Congenital Abnormalities; D004359:Drug Therapy, Combination; D005260:Female; D006373:Helminthiasis / Q000517:prevention & control*; D006801:Humans; D007231:Infant, Newborn; D007559:Ivermectin / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use*; D011247:Pregnancy; D015597:Pregnancy Complications, Parasitic / Q000517:prevention & control*; D011262:Pregnancy Trimester, Second; D047928:Premature Birth; D012987:Soil / Q000469:parasitology; D050497:Stillbirth; D014454:Uganda / Q000453:epidemiology
chemical_list: D000977:Antiparasitic Agents; D012987:Soil; D007559:Ivermectin; D015766:Albendazole